|
Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine
device in the treatment of menorrhagia. Brit
J Obstet Gynecol, 1990; 97(Aug): 690-94.
Center for Communications Programs (Population Information
Program): IUDs — a new look. Population
Reports, 1988; Series B(5).
Chi IC. Postpartum IUD insertion: Timing, route, lactation,
and uterine perforation. In: Proceedings from the Fourth International
Conference on IUDs, Butterworth-Heinemann: Boston, 1994; 219-27.
Chi IC. What we have learned from recent IUD studies: A researcher’s
perspective. Contraception,
1993; 48(Aug): 81-108.
Chi IC, Farr G. Review article: Postpartum IUD contraception
— a review of an international experience. Advances
in Contraception, 1989; 5: 127-46.
Chi IC, Wilkens L, Rogers S. Expulsions in immediate postpartum
insertions of Lippes Loop D and copper T IUDs and their counterpart
delta devices: An epidemiological analysis. Contraception,
1985; 32(2): 119-34.
Croxatto H, Ortiz M, Valdez E. IUD mechanisms of action. In:
Proceedings from the Fourth International Conference on IUDs,
Butterworth-Heinemann: Boston, 1994; 44-62.
Edelman D, Van Os W. Safety of intrauterine contraception.
Advances in Contraception, 1990;
6: 207-17.
Edelman D, Porter C. The intrauterine device and ectopic pregnancy.
Contraception, 1987; 36(1):
85-96.
Eren N, Ramos R, Gray R. Physicians vs. auxiliary nurse-midwives
as providers of IUD services: A study in Turkey and the Philippines.
Stud Fam Plann, 1983; 14(2):
43-47.
Farley TMM, Rosenberg MJ, Rowe PJ, et al. Intrauterine devices
and pelvic inflammatory disease: An international perspective.
The Lancet, 1992; 339(Mar28):
785-88.
Farr G, Amatya R. Contraceptive efficacy of the copper T380A
and the multiload Cu250 IUD in three developing countries.
Advances in Contraception, 1994; 10: 137-49.
Farr G, Amatya R, Betancourt J, et al. Clinical performance
of the TCu 380A and TCu 220 IUDs in four developing country
family planning clinics. Contraception,
1994; 50: 417-29.
Faundes A, Telles E, Cristofoletti ML, et al. The risk of inadvertent
intrauterine device insertion in women carriers of endocervical
Chlamydia trachomatis. Contraception, 1998; 58(2):105-9.
Franks AL, Beral V, Cates W, et al. Contraception and ectopic
pregnancy risk. Am J Obstet Gynecol,
1990; 163(4/part 1): 1120-23.
Hubacher D, Lara-Ricalde R, Taylor DJ, et al. Use of copper
intrauterine devices and the risk of tubal infertility among
nulligravid women. N Engl J Med, 2001; 345:561-67.
JHPIEGO. Pocket Guide for Family Planning Service Providers.
JHPIEGO: Baltimore; 1995.
JHPIEGO. IUD Guidelines for Family Planning Clinical Service
Programs: A Problem-Solving Reference Manual, 2nd ed. JHPIEGO:
Baltimore; 1993.
Ladipo OA, Farr G, Otolorin E, et al. Prevention of IUD-related
pelvic infection: The efficacy of prophylactic doxycycline at
IUD insertion. Advances in Contraception,
1991; 7: 43-54.
Larsson G, Milsom I, Jonasson K, et al. The long-term effects
of copper surface area on menstrual blood loss and iron status
in women fitted with an IUD. Contraception,
1993; 48(Nov): 471-80.
Lee NC, Rubin GL, Borucki R. The intrauterine device and pelvic
inflammatory disease revisited: New results from the Women’s
Health Study. Obstet Gynecol,
1988; 73(1): 1-6.
Lee NC, Rubin GL, Ory HW, et al. Type of intrauterine device
and the risk of pelvic inflammatory disease. Obstet
Gynecol, 1993; 62(1): 1-6.
Lee NC. What we’ve learned about IUDs. Am
J Gynecol Health, 1989; 3(3-S): 27-32.
Luukkainen T. The levonorgestrel-releasing IUD.
Brit J Fam Plann, 1993; 19: 221-24.
Maudlin W, Segal S. IUD use throughout the world: Past, present,
and future. In: Proceedings from the Fourth International Conference
on IUDs, Butterworth-Heinemann: Boston, 1994; 1-10.
Morrison CS, Sekadde-Kigondu C, Sinei SK, et al. Is the intrauterine
device appropriate contraception for HIV-1 infected women? Br
J Obstet Gynaecol, 2001; 108(8): 784-90.
O’Hanley K, Huber DH. Postpartum IUDs: Keys for success.
Contraception, 1992; 45(4):351-61.
Ortiz ME, Croxatto HB. The mode of action of IUDs. Contraception,
1987; 36(1): 37-51.
Population Crisis Committee. Access to affordable contraception
[chart]. Population Crisis Committee: Washington, DC; 1991.
Program for International Training in Health. Guidelines for
clinical procedures in family planning: A reference for trainers,
2nd ed. INTRAH: Chapel Hill, NC; 1993.
Richardson B, Morrison C, Sekadde-Kigondu C, et al. Effect
of intrauterine device use on cervical shedding of HIV-1 DNA.
AIDS, 1999; 13(15): 2091-97.
Rivera R, Chi IC, Farr G. The intrauterine device in the present
and future. Obstet Gynecol,
1993; 5: 829-32.
Rivera R, Farr G, Chi IC. The copper IUD: Safe and effective.
Family Health International: Research Triangle Park, NC; 1992.
Sastrawinata S, Farr G, Prihadi S, et al. A comparative clinical
trial of the TCu 380A, Lippes Loop D and multiload Cu 375 IUDs
in Indonesia. Contraception,
1991; 44(2): 141-54.
Shelton J. Risk of clinical pelvic inflammatory disease attributable
to an intrauterine device. Lancet, 2001; 357(9253): 443.
Sinei S, Morrison C, Sekadde-Kigondu C, et al. Complications
of use of IUDs among HIV-1 infected women. Lancet, 1998;
351(9111): 1238-41.
Sinei SKA, Schulz KF, Lamptey PR, et al. Preventing IUCD-related
pelvic infection: The efficacy of prophylactic doxycycline at
insertion. Brit J Obstet Gynecol,
1990; 97(5): 412-19.
Sivin I. Dose and age dependent ectopic pregnancy risks with
intrauterine contraception. Obstet
Gynecol, 1991; 78(2): 291-98.
Sivin I, Stern J. Health during prolonged use of levonorgestrel
20 mg/day and the Copper TCu 380Ag intrauterine contraceptive
devices: A multicenter study. Fertil
Steril, 1994; 61(1): 70-77.
Sivin I. IUDs are contraceptives, not abortifacients: A comment
on research and belief. Stud Fam Plann,
1989; 20(6): 355-59.
Sivin I, Alvarez F, Diaz J, et al. Intrauterine contraception
with copper and with levonorgestrel: A randomized study of the
TCu 380Ag and levonorgestrel 20 mg/day devices. Contraception,
1984; 30(5): 443-56.
Sivin I, Stern J, Coutinho E, et al. Prolonged intrauterine
contraception: A seven year randomized study of the levonorgestrel
20mcg/day (LNg 20) and the copper T380 Ag IUDs. Contraception,
1991; 44(5): 473-80.
Szczedrin W, Zighelboim I, Farr G, et al. Estudio comparativo
del TCu 380 A y Nova T. Rev Obstet
Ginecol Venez, 1993; 53(3): 171-75.
The Population Council and the Program for Appropriate Technology
in Health (PATH). The Copper T 380A IUD [information packet].
PATH: Seattle, Washington; 1989.
Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine
release of levonorgestrel on pelvic infection: Three year’s
comparative experience of levonorgestrel and copper releasing
intrauterine devices. Obstet Gynecol,
1991; 77(2): 261-64.
World Health Organization. Improving access to quality care
in family planning: Medical eligibility criteria for contraceptive
use. Third edition, 2004. WHO: Geneva. Available: http://www.who.int/reproductive-health/publications/RHR_00_2_medical_eligibility_criteria_3rd/index.htm.
World Health Organization. Mechanism of action, safety and
efficacy of intrauterine devices: Report of a WHO scientific
group. Technical Report Series 753. WHO: Geneva; 1987.
|
